- **DM Market Leader**: Brepocitinib Phase III data positions as first novel oral DM therapy with 30mg dose showing 1/3 patients off steroids. NDA filing Q1 2026.
- **Graves’ Innovation**: Batoclimab delivers 6-month remission in 81% of patients, with 75% off/low ATD use. FcRn mechanism validated by argenx’s VYVGART follow-on.
- **Litigation Catalyst**: Moderna trial March 2026; favorable Pfizer ruling. Global LNP enforcement could unlock $5B+ damages.
- **Pipeline Expansion**: 11 registrational trials across 6 indications. Sjögren’s Phase II targeting ESSDAI; Pulmovant PH-ILD data H2 2026.
- **Capital Strength**: $4.4B cash to fund pipeline through profitability; $500M buyback authorization.


**【CEO Summary Section】**
- **Brepocitinib Phase III Success**: VALOR trial in dermatomyositis (DM) met all endpoints with 30mg dose showing rapid, deep responses across muscle and skin metrics. 1/3 of patients achieved TIS40 and minimal/no steroid use at week 52. NDA filing for DM expected Q1 2026.
- **Graves' Disease Breakthrough**: Batoclimab showed durable remission in 17/21 patients off therapy for 6 months, with 75% off/low ATD use. Data supports disease-modifying potential via deep IgG suppression.
- **Financial Strength**: $4.4B cash, no debt. Strong pipeline with 11 registrational trials across DM, Graves', MG, CIDP, Sjögren’s, and RA.
- **Litigation Progress**: Favorable ruling in Pfizer case; Moderna trial set for March 2026. International cases progressing in UPC, Canada, Japan.
- **Upcoming Events**: Investor Day on Dec 11, 2025 to detail commercial strategy and pipeline updates.

**【Q&A Key Highlights】**
- **Competitive Landscape**: Argenx’s VYVGART in Graves’ validates FcRn strategy. Roivant’s higher IgG reduction (≥70%) in Phase II linked to better ATD discontinuation rates. FcRn safety/tolerability优势 in Graves’ seen as key differentiator.
- **Sjögren’s & Other Indications**: IMVT-1402 Phase II in Sjögren’s targeting ESSDAI; potential first-in-class with deeper IgG suppression. Pulmovant’s mosli for PH-ILD Phase IIb data expected H2 2026.
- **LNP Litigation**: Moderna U.S. sales <50% of global; 1498 patent defense scope narrow. International trials could yield decisions in 2026.
- **DM Launch Strategy**: No direct analogs; focus on unmet need in DM with oral, scalable therapy. Global enrollment in NIU trial progressing.
- **Ted Study**: Delayed data release to align with evolving competitive landscape. Focus on Graves’ as upstream opportunity.


Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

IMVT

IMVT fundamentals

You can ask Aime